Search details
1.
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
N Engl J Med
; 388(23): 2145-2158, 2023 06 08.
Article
in English
| MEDLINE | ID: mdl-36972026
2.
Survival with Cemiplimab in Recurrent Cervical Cancer.
N Engl J Med
; 386(6): 544-555, 2022 02 10.
Article
in English
| MEDLINE | ID: mdl-35139273
3.
Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab.
Oncologist
; 29(1): 25-35, 2024 Jan 05.
Article
in English
| MEDLINE | ID: mdl-37523661
4.
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.
N Engl J Med
; 385(20): 1856-1867, 2021 11 11.
Article
in English
| MEDLINE | ID: mdl-34534429
5.
A systematic review of stage IVA cervical cancer treatment: Challenges in the management of an understudied group.
Gynecol Oncol
; 187: 120-127, 2024 May 16.
Article
in English
| MEDLINE | ID: mdl-38759518
6.
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Gynecol Oncol
; 187: 128-138, 2024 Jun 03.
Article
in English
| MEDLINE | ID: mdl-38833992
7.
Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer - An NRG/GOG study.
Gynecol Oncol
; 181: 54-59, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38134754
8.
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.
Gynecol Oncol
; 184: 168-177, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38325276
9.
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer.
Int J Gynecol Cancer
; 34(4): 469-477, 2024 Apr 01.
Article
in English
| MEDLINE | ID: mdl-38101816
10.
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04).
Int J Gynecol Cancer
; 2024 Jun 10.
Article
in English
| MEDLINE | ID: mdl-38858106
11.
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design.
Int J Gynecol Cancer
; 2024 Apr 16.
Article
in English
| MEDLINE | ID: mdl-38627035
12.
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 24(4): 392-402, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36878237
13.
Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(5): 468-482, 2023 05.
Article
in English
| MEDLINE | ID: mdl-37080223
14.
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 24(12): 1334-1348, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-38039991
15.
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Cancer
; 129(12): 1846-1855, 2023 06 15.
Article
in English
| MEDLINE | ID: mdl-37060236
16.
Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or Both.
Oncologist
; 28(10): e977-e980, 2023 10 03.
Article
in English
| MEDLINE | ID: mdl-37665777
17.
Cervical cancer treatment update: A Society of Gynecologic Oncology clinical practice statement.
Gynecol Oncol
; 179: 115-122, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-37980766
18.
Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study.
Gynecol Oncol
; 171: 141-150, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36898292
19.
Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032).
Gynecol Oncol
; 178: 161-169, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37890345
20.
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
Gynecol Oncol
; 170: 300-308, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36758420